Acrivon Therapeutics, Inc. (ACRV)
| Previous Close | 8.14 |
| Open | 8.14 |
| Bid | 8.35 x 100 |
| Ask | 8.48 x 100 |
| Day's Range | 7.98 - 8.59 |
| 52 Week Range | 3.19 - 14.30 |
| Volume | |
| Avg. Volume | 794,224 |
| Market Cap | 259.817M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.74 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.13 |
ZacksIs a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season?
Acrivon Therapeutics (ACRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Simply Wall St.While institutions own 26% of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), private equity firms are its largest shareholders with 50% ownership
Key Insights Significant control over Acrivon Therapeutics by private equity firms implies that the general public has...
GlobeNewswireAcrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
• Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) are being presented• A 50% confirmed overall response rate observed with ACR-368 in OncoSignature-positive gynecological (ovarian and endometrial) cancers• Initial clinical validation of AP3 patient selection platform, demonstrated ability to prospectively predict ACR-368 RECIST responders (p-value = 0.0038)• ACR-2316, a potential first-in-class
